These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 20873947)
1. Will the newer oral MS agents be welcomed by managed care organizations? Lipsy RJ Am J Manag Care; 2010 Sep; 16(8 Suppl):S227-33. PubMed ID: 20873947 [TBL] [Abstract][Full Text] [Related]
2. Emerging oral agents for multiple sclerosis. Fox EJ Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946 [TBL] [Abstract][Full Text] [Related]
3. New oral drugs for multiple sclerosis. Gasperini C; Ruggieri S Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371 [TBL] [Abstract][Full Text] [Related]
5. Guidelines and best practices for appropriate use of dalfampridine in managed care populations. Miravalle AA Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S154-60. PubMed ID: 21761954 [TBL] [Abstract][Full Text] [Related]
6. New and emerging disease modifying therapies for multiple sclerosis. Saidha S; Eckstein C; Calabresi PA Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673 [TBL] [Abstract][Full Text] [Related]
7. Treatment options for multiple sclerosis: current and emerging therapies. Gawronski KM; Rainka MM; Patel MJ; Gengo FM Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847 [TBL] [Abstract][Full Text] [Related]
8. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Lugaresi A Expert Opin Drug Deliv; 2009 Sep; 6(9):995-1002. PubMed ID: 19637982 [TBL] [Abstract][Full Text] [Related]
10. Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis. Brandes DW; Raimundo K; Agashivala N; Kim E J Med Econ; 2013; 16(4):547-51. PubMed ID: 23391123 [TBL] [Abstract][Full Text] [Related]
11. The current landscape and unmet needs in multiple sclerosis. Markowitz CE Am J Manag Care; 2010 Sep; 16(8 Suppl):S211-8. PubMed ID: 20873945 [TBL] [Abstract][Full Text] [Related]
12. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Sipe JC Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859 [TBL] [Abstract][Full Text] [Related]
13. Cost of oral antibiotic therapy. Nightingale CH; Quintiliani R Pharmacotherapy; 1997; 17(2):302-7. PubMed ID: 9085322 [TBL] [Abstract][Full Text] [Related]
14. Principles of a new treatment algorithm in multiple sclerosis. Hartung HP; Montalban X; Sorensen PS; Vermersch P; Olsson T Expert Rev Neurother; 2011 Mar; 11(3):351-62. PubMed ID: 21375441 [TBL] [Abstract][Full Text] [Related]
15. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394 [TBL] [Abstract][Full Text] [Related]
17. Fingolimod: a novel immunosuppressant for multiple sclerosis. Brown BA; Kantesaria PP; McDevitt LM Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617 [TBL] [Abstract][Full Text] [Related]
18. Cladribine as a therapeutic option in multiple sclerosis. Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757 [TBL] [Abstract][Full Text] [Related]
19. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs]. Hecht B Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402 [TBL] [Abstract][Full Text] [Related]
20. Cladribine for multiple sclerosis: review and current status. Sipe JC Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]